OPTIMIZER Smart Post-Approval Study
Investigator: Jared Green, DO
The purpose of this post approval study (PAS) is to evaluate the safety of the long-term use of the OPTIMIZER Smart device and Cardiac Contractility Modulation therapy on the quality of life and heart failure symptoms for patients who remain symptomatic despite optimized guideline directed heart failure medications.
|EVOLVE-MI: Myocardial Infarction
A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction.
Principal Investigator: Aniruddha Singh, MD